Drugs / GS001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT04728841 | Mar 2021 → Jul 2028 expected | hemophilia A | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GS001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04728841 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “an adeno-associated virus serotype 8 (AAV8)-based vector encoding B-domain-deleted factor VIII” PMID 41813646 ↗ Mar 2026 |
| Route | Intravenous | “single intravenous infusion of GS001” NCT04728841 ↗ |